--- title: "Trevi Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/285302951.md" datetime: "2026-05-06T03:15:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285302951.md) - [en](https://longbridge.com/en/news/285302951.md) - [zh-HK](https://longbridge.com/zh-HK/news/285302951.md) --- # Trevi Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.09, missing the estimate of USD -0.0722. EBIT: As of FY2026 Q1, the actual value is USD -16.61 M. #### Cash, Cash Equivalents, and Marketable Securities Trevi Therapeutics, Inc. ended the first quarter of 2026 with $171.8 million in cash, cash equivalents, and marketable securities. Cash and cash equivalents were $19,412 thousand as of March 31, 2026, compared to $18,914 thousand as of December 31, 2025. Marketable securities were $152,371 thousand as of March 31, 2026, down from $169,346 thousand as of December 31, 2025. Following a common stock offering in April 2026, which generated net proceeds of approximately $162 million, the company expects its current cash resources to extend its cash runway into 2030. #### Working Capital Working capital was $169,006 thousand as of March 31, 2026, a decrease from $181,907 thousand as of December 31, 2025. #### Total Assets Total assets amounted to $179,606 thousand as of March 31, 2026, compared to $193,439 thousand as of December 31, 2025. #### Stockholders’ Equity Stockholders’ equity was $172,127 thousand as of March 31, 2026, compared to $183,244 thousand as of December 31, 2025. #### Research and Development (R&D) Expenses R&D expenses increased by 27.27% to $9,941 thousand for the first quarter of 2026, up from $7,811 thousand in the same period in 2025. This increase was primarily driven by higher clinical development expenses for Phase 1 NDA supportive studies, Phase 3 IPF-related chronic cough trials, and the Phase 2b RCC trial. #### General and Administrative (G&A) Expenses G&A expenses rose by 35.86% to $4,971 thousand for the first quarter of 2026, compared to $3,659 thousand in the first quarter of 2025. This was mainly due to increased legal fees for intellectual property filings, as well as higher non-cash stock option expenses and other personnel-related costs. #### Total Operating Expenses Total operating expenses for the first quarter of 2026 were $14,912 thousand, an increase from $11,470 thousand in the same period of 2025. #### Loss from Operations Loss from operations for the first quarter of 2026 was - $14,912 thousand, compared to - $11,470 thousand in the first quarter of 2025. #### Other Income, Net Other income, net, increased by 51.92% to $1,700 thousand for the first quarter of 2026, up from $1,119 thousand in the corresponding period of 2025. This was primarily due to increased interest income from higher invested cash equivalents and marketable securities balances. #### Net Loss Trevi Therapeutics, Inc. reported a net loss of - $13,192 thousand for the first quarter of 2026, compared to a net loss of - $10,340 thousand in the same period in 2025. #### Outlook / Guidance Trevi Therapeutics, Inc. anticipates its cash resources will fund operations into 2030, potentially through FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement. The company plans to initiate multiple clinical trials in the second quarter of 2026, including a first Phase 3 trial for IPF-related chronic cough and a Phase 2b trial for refractory chronic cough (RCC). Topline results are expected from the first IPF-related chronic cough Phase 3 trial in the first half of 2028, and from the second IPF-related chronic cough Phase 3 trial, the non-IPF ILD-related chronic cough Phase 2b trial, and the RCC Phase 2b trial in the second half of 2027. ### Related Stocks - [TRVI.US](https://longbridge.com/en/quote/TRVI.US.md) ## Related News & Research - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)